WO2002100344A3 - Amino acid conjugates providing for sustained systemic concentrations of gaba analogues - Google Patents
Amino acid conjugates providing for sustained systemic concentrations of gaba analogues Download PDFInfo
- Publication number
- WO2002100344A3 WO2002100344A3 PCT/US2002/018493 US0218493W WO02100344A3 WO 2002100344 A3 WO2002100344 A3 WO 2002100344A3 US 0218493 W US0218493 W US 0218493W WO 02100344 A3 WO02100344 A3 WO 02100344A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino acid
- systemic concentrations
- acid conjugates
- sustained systemic
- gaba analogues
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
- C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C317/50—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
- C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
- C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02744288A EP1412324A4 (en) | 2001-06-11 | 2002-06-11 | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
US10/480,293 US7420002B2 (en) | 2001-06-11 | 2002-06-11 | Amino acid conjugates providing for sustained systemic concentrations of GABA analogues |
JP2003503171A JP2005501013A (en) | 2001-06-11 | 2002-06-11 | Amino acid conjugates with sustained systemic concentrations of GABA analogs |
AU2002345638A AU2002345638A1 (en) | 2001-06-11 | 2002-06-11 | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
US12/128,225 US7645797B2 (en) | 2001-06-11 | 2008-05-28 | Amino acid conjugates providing for sustained systemic concentrations of GABA analogues |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29773201P | 2001-06-11 | 2001-06-11 | |
US60/297,732 | 2001-06-11 | ||
US36461902P | 2002-03-18 | 2002-03-18 | |
US60/364,619 | 2002-03-18 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10480293 A-371-Of-International | 2002-06-11 | ||
US12/128,225 Continuation US7645797B2 (en) | 2001-06-11 | 2008-05-28 | Amino acid conjugates providing for sustained systemic concentrations of GABA analogues |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002100344A2 WO2002100344A2 (en) | 2002-12-19 |
WO2002100344A3 true WO2002100344A3 (en) | 2004-02-12 |
Family
ID=31498147
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/018493 WO2002100344A2 (en) | 2001-06-11 | 2002-06-11 | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
Country Status (5)
Country | Link |
---|---|
US (3) | US7420002B2 (en) |
EP (1) | EP1412324A4 (en) |
JP (1) | JP2005501013A (en) |
AU (1) | AU2002345638A1 (en) |
WO (1) | WO2002100344A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7790708B2 (en) | 2001-06-11 | 2010-09-07 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
US9238616B2 (en) | 2001-06-11 | 2016-01-19 | Xenoport, Inc. | Prodrugs of gaba analogs, compositions and uses thereof |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1412324A4 (en) * | 2001-06-11 | 2004-09-29 | Xenoport Inc | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
US6955888B2 (en) * | 2001-06-11 | 2005-10-18 | Xenoport | Methods of screening agents, conjugates or conjugate moieties for transport by a PEPT2 transporter |
US6818787B2 (en) | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
US7612112B2 (en) | 2001-10-25 | 2009-11-03 | Depomed, Inc. | Methods of treatment using a gastric retained gabapentin dosage |
TWI312285B (en) | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
KR100747464B1 (en) * | 2002-01-05 | 2007-08-09 | 엘지전자 주식회사 | Timer based Stall Avoidance method in HSDPA system |
EP1490043A4 (en) | 2002-03-26 | 2007-05-30 | Merck & Co Inc | Spirocyclic amides as cannabinoid receptor modulators |
US20050153928A1 (en) * | 2002-05-07 | 2005-07-14 | Holick Michael F. | Conjugates comprising a central nervous system-active drug linked to glucuronic acid or glucosamine through an amide bond and uses thereof |
US7183259B2 (en) | 2002-05-17 | 2007-02-27 | Xenoport | Amino acid conjugates providing for sustained systemic concentrations of GABA analogues |
US7589233B2 (en) * | 2003-07-29 | 2009-09-15 | Signature R&D Holdings, Llc | L-Threonine derivatives of high therapeutic index |
US8173840B2 (en) * | 2003-07-29 | 2012-05-08 | Signature R&D Holdings, Llc | Compounds with high therapeutic index |
MXPA06003043A (en) | 2003-09-17 | 2006-05-31 | Xenoport Inc | Treating or preventing restless legs syndrome using prodrugs of gaba analogs. |
JP2007506729A (en) * | 2003-09-25 | 2007-03-22 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | Prodrugs of amino acids with affinity for α2δ protein |
WO2005041925A2 (en) * | 2003-10-31 | 2005-05-12 | Alza Corporation | Compositions and dosage forms for enhanced absorption |
FR2883873B1 (en) * | 2005-03-31 | 2009-07-10 | Pharmamens Sarl | AGE INHIBITORS |
US20090176882A1 (en) | 2008-12-09 | 2009-07-09 | Depomed, Inc. | Gastric retentive gabapentin dosage forms and methods for using same |
MY147787A (en) | 2006-06-27 | 2013-01-31 | Otsuka Pharma Co Ltd | Powder inhaler |
US8828665B2 (en) | 2007-02-16 | 2014-09-09 | Ark Diagnostics, Inc. | Compounds and methods for use in detecting gabapentin |
JP2010043063A (en) * | 2008-05-09 | 2010-02-25 | Agency For Science Technology & Research | Diagnosis and treatment of kawasaki disease |
US8168756B2 (en) | 2008-10-24 | 2012-05-01 | Ark Diagnostics, Inc. | Levetiracetam immunoassays |
US20110130454A1 (en) * | 2009-11-24 | 2011-06-02 | Xenoport, Inc. | Prodrugs of gamma-amino acid, alpha-2-delta ligands, pharmaceutical compositions and uses thereof |
US20110124705A1 (en) * | 2009-11-24 | 2011-05-26 | Xenoport, Inc. | Prodrugs of alpha-2-delta ligands, pharmaceutical compositions and uses thereof |
US9199914B2 (en) * | 2010-02-03 | 2015-12-01 | Meh Associates, Inc. | Multiple substituted fluoromethanes as selective and bioactive isosteres |
CN103228142A (en) | 2010-09-28 | 2013-07-31 | 加利福尼亚大学董事会 | GABA agonists in treatment of disorders associated with metabolic syndrome and GABA combinations in treatment or prophylaxis of type I diabetes |
JP5230847B2 (en) | 2011-04-20 | 2013-07-10 | 財団法人乙卯研究所 | Silicon-containing carboxylic acid derivatives |
JP5572783B1 (en) | 2012-10-18 | 2014-08-13 | 有限会社ケムフィズ | Silicon-containing carboxylic acid derivatives |
US9970929B2 (en) | 2013-01-18 | 2018-05-15 | Ark Diagnostics, Inc. | Voriconazole immunoassays |
ES2674704T3 (en) | 2013-02-13 | 2018-07-03 | Ark Diagnostics, Inc. | Posaconazole Immunoassays |
CN105997970A (en) * | 2015-12-16 | 2016-10-12 | 南昌大学 | Application of gamma-aminobutyric acid in preparation of gastric mucosa protective agent |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6140366A (en) * | 1990-11-27 | 2000-10-31 | Northwestern University | GABA and L-glutamic acid analogs for antiseizure treatment |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2996431A (en) | 1953-12-16 | 1961-08-15 | Barry Richard Henry | Friable tablet and process for manufacturing same |
US3402240A (en) | 1957-06-25 | 1968-09-17 | Pfizer & Co C | Medicinal tablet and process of making same |
US3139383A (en) | 1961-06-26 | 1964-06-30 | Norton Co | Encapsulated time release pellets and method for encapsulating the same |
SU298556A1 (en) | 1969-12-25 | 1971-06-10 | Л. А. Вакусевич , О. В. Давыдова | |
US3962414A (en) | 1972-04-27 | 1976-06-08 | Alza Corporation | Structured bioerodible drug delivery device |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3811444A (en) | 1972-12-27 | 1974-05-21 | Alza Corp | Bioerodible ocular device |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
DE2336218C3 (en) | 1973-07-17 | 1985-11-14 | Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz | Oral dosage form |
US3992518A (en) | 1974-10-24 | 1976-11-16 | G. D. Searle & Co. | Method for making a microsealed delivery device |
GB1478759A (en) | 1974-11-18 | 1977-07-06 | Alza Corp | Process for forming outlet passageways in pills using a laser |
US4087544A (en) | 1974-12-21 | 1978-05-02 | Warner-Lambert Company | Treatment of cranial dysfunctions using novel cyclic amino acids |
DE2460891C2 (en) | 1974-12-21 | 1982-09-23 | Gödecke AG, 1000 Berlin | 1-aminomethyl-1-cycloalkaneacetic acids and their esters, processes for their preparation and medicaments containing these compounds |
US4093709A (en) | 1975-01-28 | 1978-06-06 | Alza Corporation | Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates) |
US4063064A (en) | 1976-02-23 | 1977-12-13 | Coherent Radiation | Apparatus for tracking moving workpiece by a laser beam |
US4079038A (en) | 1976-03-05 | 1978-03-14 | Alza Corporation | Poly(carbonates) |
US4066747A (en) | 1976-04-08 | 1978-01-03 | Alza Corporation | Polymeric orthoesters housing beneficial drug for controlled release therefrom |
US4070347A (en) | 1976-08-16 | 1978-01-24 | Alza Corporation | Poly(orthoester) co- and homopolymers and poly(orthocarbonate) co- and homopolymers having carbonyloxy functionality |
US4285987A (en) | 1978-10-23 | 1981-08-25 | Alza Corporation | Process for manufacturing device with dispersion zone |
US4200098A (en) | 1978-10-23 | 1980-04-29 | Alza Corporation | Osmotic system with distribution zone for dispensing beneficial agent |
US4434153A (en) | 1982-03-22 | 1984-02-28 | Alza Corporation | Drug delivery system comprising a reservoir containing a plurality of tiny pills |
US4421736A (en) | 1982-05-20 | 1983-12-20 | Merrel Dow Pharmaceuticals Inc. | Sustained release diethylpropion compositions |
US4721613A (en) | 1982-12-13 | 1988-01-26 | Alza Corporation | Delivery system comprising means for shielding a multiplicity of reservoirs in selected environment of use |
US4508728A (en) | 1984-05-24 | 1985-04-02 | Kineshiro Nagai | Method of treating inflammatory diseases |
ATE99698T1 (en) | 1985-10-14 | 1994-01-15 | Nippon Zoki Pharmaceutical Co | PEPTIDES. |
DE3703938A1 (en) * | 1986-02-12 | 1987-09-10 | Mitsubishi Electric Corp | PARTICLE ACCELERATOR |
US4820523A (en) | 1986-04-15 | 1989-04-11 | Warner-Lambert Company | Pharmaceutical composition |
US4752470A (en) | 1986-11-24 | 1988-06-21 | Mehta Atul M | Controlled release indomethacin |
US4816263A (en) | 1987-10-02 | 1989-03-28 | Alza Corporation | Dosage form for treating cardiovascular diseases comprising isradipine |
US4908353A (en) | 1987-10-16 | 1990-03-13 | Nippon Zoki Pharmaceutical Co., Ltd. | Novel dipeptide useful as a plant growth regulator |
US4853229A (en) | 1987-10-26 | 1989-08-01 | Alza Corporation | Method for adminstering tiny pills |
US5094848A (en) | 1989-06-30 | 1992-03-10 | Neorx Corporation | Cleavable diphosphate and amidated diphosphate linkers |
US5084479A (en) | 1990-01-02 | 1992-01-28 | Warner-Lambert Company | Novel methods for treating neurodegenerative diseases |
AU9137091A (en) | 1990-11-27 | 1992-06-25 | Northwestern University | Gaba and l-glutamic acid analogs for antiseizure treatment |
HU222776B1 (en) | 1992-05-20 | 2003-10-28 | Northwestern University | New hexanoic acid and butanoic acid intermediates for producing (s)-(+)-4-amino-3-(2-methyl-propil)-butanoic acid derivative |
RU2107691C1 (en) | 1995-03-02 | 1998-03-27 | Дейгин Владислав Исакович | Peptide and method for its preparation |
US5929088A (en) | 1996-02-07 | 1999-07-27 | Warner-Lambert Company | Cyclic amino acids as pharmaceutical agents |
PL185990B1 (en) | 1996-03-14 | 2003-09-30 | Warner Lambert Co | Novel bridge-type cyclic amino acids as pharmaceutic agents |
IL125544A (en) | 1996-03-14 | 2002-03-10 | Warner Lambert Co | Substituted cyclic amino acids and pharmaceutical compositions containing them |
HU228426B1 (en) | 1996-07-24 | 2013-03-28 | Warner Lambert Co | Use of isobutylgaba and its derivatives for the preparation of pharmaceuticals for treating pain |
US6375987B1 (en) | 1996-10-01 | 2002-04-23 | Gattefossé, S.A. | Process for the manufacture of pharmaceutical composition with modified release of active principle comprising the matrix |
DE69737719D1 (en) | 1996-10-23 | 2007-06-21 | Warner Lambert Co | SUBSTITUTED GAMMA AMINOBUTTERIC ACID DERIVATIVES AS DRUGS |
AU8668598A (en) | 1997-08-20 | 1999-03-08 | University Of Oklahoma, The | Gaba analogs to prevent and treat gastrointestinal damage |
PL199794B1 (en) | 1997-10-27 | 2008-10-31 | Warner Lambert Co | Intermediate compounds for producing cyclic amino acids derivatives |
NZ503963A (en) | 1997-12-16 | 2002-09-27 | Warner Lambert Co | 1-substituted-1-aminomethyl-cycloalkane derivatives, or gabapentin analogues, preparation and use in the treatment of neurological disorders |
CA2304967C (en) | 1997-12-16 | 2005-06-14 | Warner-Lambert Company | 4(3)substituted-4(3)-aminomethyl-(thio)pyran or -piperidine derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders |
KR20010033154A (en) | 1997-12-16 | 2001-04-25 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | Novel Amines as Pharmaceutical Agents |
AU2463099A (en) | 1998-01-23 | 1999-08-09 | Warner-Lambert Company | Gabapentin and its derivatives for the treatment of muscular and skeletal pain |
AU757445B2 (en) | 1998-05-26 | 2003-02-20 | Warner-Lambert Company | Conformationally constrained amino acid compounds having affinity for the alpha2delta subunit of a calcium channel |
FR2779651B1 (en) | 1998-06-16 | 2001-04-20 | Gattefosse Ets Sa | PROCESS FOR THE MANUFACTURE OF SUSTAINED RELEASE TABLETS OF ACTIVE INGREDIENT (S) HAVING ZERO-SIZE DISSOLUTION KINETICS |
US6171615B1 (en) | 1998-07-06 | 2001-01-09 | Gattefoss{acute over (e)} | Sustained release theophylline formulations, excipient systems and methods of production |
ATE280154T1 (en) | 1998-09-14 | 2004-11-15 | Warner Lambert Co | BRANCHED ALKYLPYRROLIDINE-3-CARBONIC ACIDS |
DE69934813T2 (en) | 1998-10-16 | 2007-10-11 | Warner-Lambert Company Llc | USE OF GABA ANALOGUES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF MANY AND BIPOLAR DISEASES |
AU1602100A (en) | 1998-11-25 | 2000-06-13 | Warner-Lambert Company | Improved gamma amino butyric acid analogs |
EP1031350A1 (en) | 1999-02-23 | 2000-08-30 | Warner-Lambert Company | Use of a gabapentin-analog for the manufacture of a medicament for preventing and treating visceral pain |
US7413536B1 (en) | 1999-09-14 | 2008-08-19 | Xenoport, Inc. | Substrates and screening methods for transport proteins |
GB2362646A (en) | 2000-05-26 | 2001-11-28 | Warner Lambert Co | Cyclic amino acid derivatives useful as pharmaceutical agents |
CZ20024110A3 (en) | 2000-06-26 | 2003-10-15 | Warner-Lambert Company | Medicament for treating sleep disorders |
GB2365425A (en) | 2000-08-01 | 2002-02-20 | Parke Davis & Co Ltd | Alkyl amino acid derivatives useful as pharmaceutical agents |
EP1343805A4 (en) | 2000-10-06 | 2005-07-20 | Xenoport Inc | Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration |
AU2002243204A1 (en) | 2000-10-06 | 2002-06-11 | Xenoport, Inc. | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs |
AU2002230398A1 (en) * | 2000-10-06 | 2002-04-29 | Xenoport, Inc. | Bile-acid conjugates for providing sustained systemic concentrations of drugs |
WO2002028882A1 (en) | 2000-10-06 | 2002-04-11 | Xenoport, Inc. | Bile acid prodrugs of l-dopa and their use in the sustained treatment of parkinsonism |
AU2002239257A1 (en) | 2000-11-17 | 2002-06-03 | Xenoport, Inc. | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
EP1412324A4 (en) * | 2001-06-11 | 2004-09-29 | Xenoport Inc | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
US6833140B2 (en) * | 2001-06-11 | 2004-12-21 | Xenoport, Inc. | Orally administered dosage forms of GABA analog prodrugs having reduced toxicity |
-
2002
- 2002-06-11 EP EP02744288A patent/EP1412324A4/en not_active Withdrawn
- 2002-06-11 JP JP2003503171A patent/JP2005501013A/en active Pending
- 2002-06-11 AU AU2002345638A patent/AU2002345638A1/en not_active Abandoned
- 2002-06-11 WO PCT/US2002/018493 patent/WO2002100344A2/en not_active Application Discontinuation
- 2002-06-11 US US10/480,293 patent/US7420002B2/en not_active Expired - Fee Related
- 2002-06-12 US US10/167,381 patent/US20030181390A1/en not_active Abandoned
-
2008
- 2008-05-28 US US12/128,225 patent/US7645797B2/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6140366A (en) * | 1990-11-27 | 2000-10-31 | Northwestern University | GABA and L-glutamic acid analogs for antiseizure treatment |
US6255345B1 (en) * | 1990-11-27 | 2001-07-03 | Northwestern University | GABA and L-glutamic acid analogs for antiseizure treatment |
US6291526B1 (en) * | 1990-11-27 | 2001-09-18 | Northwestern University | GABA and L-glutamic acid analogs for antiseizure treatment |
US6342529B1 (en) * | 1990-11-27 | 2002-01-29 | Northwestern University | GABA and L-glutamic acid analogs for antiseizure treatment |
Non-Patent Citations (1)
Title |
---|
See also references of EP1412324A4 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7790708B2 (en) | 2001-06-11 | 2010-09-07 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
US9238616B2 (en) | 2001-06-11 | 2016-01-19 | Xenoport, Inc. | Prodrugs of gaba analogs, compositions and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
EP1412324A2 (en) | 2004-04-28 |
US20080226716A1 (en) | 2008-09-18 |
US7645797B2 (en) | 2010-01-12 |
AU2002345638A1 (en) | 2002-12-23 |
US7420002B2 (en) | 2008-09-02 |
WO2002100344A2 (en) | 2002-12-19 |
EP1412324A4 (en) | 2004-09-29 |
US20030181390A1 (en) | 2003-09-25 |
US20040254344A1 (en) | 2004-12-16 |
JP2005501013A (en) | 2005-01-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002100344A3 (en) | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues | |
WO2003099338A3 (en) | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues | |
WO2002042414A3 (en) | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues | |
WO2002032376A3 (en) | Bile-acid conjugates for providing sustained systemic concentrations of drugs | |
HK1076605A1 (en) | Formulations | |
CA2411754A1 (en) | 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoic acid and compositions for delivering active agents | |
WO2004043363A8 (en) | Protein-stabilized liposomal formulations of pharmaceutical agents | |
MXPA03011041A (en) | Pharmaceutical compositions comprising orlistat and fatty acids and/or salts thereof. | |
WO2003045331A3 (en) | Formulations for oral administration of cromolyn sodium | |
MXPA02002249A (en) | Palatable pharmaceutical compositions for companion animals. | |
TNSN01130A1 (en) | EXTENDED RELEASE FORMULATIONS FOR GROWTH HORMONE SECRETAGOGUES | |
IL165065A0 (en) | Pharmaceutical compositions containing roflumilastfor treatment of eye disease | |
DE69932835D1 (en) | MEDICAL AEROSOL PREPARATION | |
WO2002074247A8 (en) | Pharmaceutical formulations for sustained release | |
IL145430A0 (en) | N-cyanomethyl amides, processes for the preparation thereof and pharmaceutical compositions containing the same | |
PA8563901A1 (en) | ESTERES HYDROXAMATE ACID N- (4-PHENYL-REPLACED) -ANTRANILICO | |
WO2004064758A3 (en) | Improved oral delivery of peptides | |
IL148874A0 (en) | Sulfonyl amino acid derivatives, their preparation and pharmaceutical compositions containing them | |
MXPA04000028A (en) | Pharmaceutical formulation for the intramuscular administration of fulvestrant. | |
BR0311642A (en) | Increased Release Sodium Divalproex Formulation | |
WO2004069187A3 (en) | Drug formulation and delivery using crystalline methylated cyclodextrins | |
WO2003028624A3 (en) | Levothyroxine compositions and methods | |
WO2004058137A3 (en) | Compounds for oral dosage of active substances requiring a taste masking | |
WO2004033484A3 (en) | Use of stable glutamine derivatives to improve drug absorption | |
WO2003075834A3 (en) | Activated protein c formulations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002744288 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003503171 Country of ref document: JP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 2002744288 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10480293 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002744288 Country of ref document: EP |